OBJECTIVES The objective of this study was to investigate the incidence, treatment and survival of Stanford type B aortic dissection (BTAD) during 20 years in the Finnish population. METHODS Data collection was made from the Nationwide Care Register for Health Care, Finnish National Institute for Health and Welfare. All patients over 15 years of age with BTAD from 2000 to 2019 were included in the study. A data search of the Registry of Death Cause (Statistic Finland) was carried out to identify the date and cause of death. RESULTS There were 1742 cases of BTAD during the study period. BTAD represented 45.6% of all aortic dissections leading to hospital admission. Incidence for BTAD was 1.62 per 100 000 inhabitants per year. The median survival was 12.7 years [95% confidence interval (CI) 9.63-14.7], 12.4 years (95% CI 10.5-14.4) and 8.6 years (95% CI 7.5-9.7) for patients treated with thoracic endovascular aortic repair (TEVAR), surgery and medical treatment (MT), respectively. Survival was significantly better after TEVAR and surgery, compared to MT only (P < 0.001). Age-adjusted survival was significantly better after TEVAR compared to patients treated with MT or surgery (hazard ratio 0.578, 95% CI 0.420-0.794, P < 0.001). Aortic-related death was the most common cause of death in all groups (41%). CONCLUSIONS The incidence of BTAD seems to be similar in the Finnish population compared to other populational studies. Patients treated with TEVAR had significantly better survival compared to other patients. A high risk for late aortic-related death should be recognized in patients with BTAD.

中文翻译：

---

B 型主动脉夹层二十年经验：芬兰基于人群的国家登记研究。

目的 本研究的目的是调查芬兰人群 20 年来斯坦福 B 型主动脉夹层 (BTAD) 的发病率、治疗和生存情况。方法 数据收集来自芬兰国家健康与福利研究所的全国医疗保健登记册。该研究纳入了2000年至2019年所有年龄超过15岁的BTAD患者。对死亡原因登记处（芬兰统计局）进行了数据检索，以确定死亡日期和原因。结果 研究期间共有 1742 例 BTAD 病例。BTAD 占所有入院主动脉夹层的 45.6%。BTAD 的发病率为每年每 10 万居民 1.62 例。接受胸主动脉腔内修复术 (TEVAR) 治疗的患者的中位生存期分别为 12.7 年 [95% 置信区间 (CI) 9.63-14.7]、12.4 年 (95% CI 10.5-14.4) 和 8.6 年 (95% CI 7.5-9.7) ）、手术治疗（MT）和药物治疗（MT）。与仅 MT 相比，TEVAR 和手术后的生存率显着提高 (P < 0.001)。与接受 MT 或手术治疗的患者相比，TEVAR 治疗后的年龄调整生存率显着提高（风险比 0.578，95% CI 0.420-0.794，P < 0.001）。主动脉相关死亡是所有群体中最常见的死亡原因（41%）。结论 与其他人群研究相比，芬兰人群中 BTAD 的发病率似乎相似。与其他患者相比，接受 TEVAR 治疗的患者的生存率显着提高。应认识到 BTAD 患者晚期主动脉相关死亡的高风险。